| Identification | Back Directory | [Name]
LY 2801653 dihydrochloride | [CAS]
1206801-37-7 | [Synonyms]
CS-1046
LY2801653 HCl
LY2801653 2HCl
LY-2801653 dihydrochloride
LY 2801653 dihydrochloride
Merestinib dihydrochloride
LY2801653 (dihydrochloride)
Merestinib(LY2801653 dihydrochloride)
LY-2801653 DIHYDROCHLORIDE; LY 2801653 DIHYDROCHLORIDE
Merestinib dihydrochloride (LY2801653 dihydrochloride)
LY-2801653 DIHYDROCHLORIDE; LY 2801653 DIHYDROCHLORIDE;LY2801653
N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide dihydrochloride
N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-methyl-2-oxo-3-pyridinecarboxamide hydrochloride (1:2) | [Molecular Formula]
C30H22F2N6O3.2(HCl) | [MDL Number]
MFCD26142925 | [MOL File]
1206801-37-7.mol | [Molecular Weight]
589 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C, sealed storage, away from moisture | [solubility ]
DMSO: ≥ 100 mg/mL (159.88 mM) | [form ]
Powder | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
N-[3-Fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide dihydrochloride is used as a reactant/reagent in synthetic preparation of amidophenoxyindazoles as inhibitors of c-Met. | [in vivo]
Merestinib (LY2801653) demonstrates anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects. Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min. Merestinib (LY2801653) treatment inhibits MET phosphorylation with a composite TED50 (50 % target inhibition dose) of 1.2 mg/kg and a composite TED90 (90 % target inhibition dose) of 7.4 mg/kg[1]. Merestinib (LY2801653) (20 mg/kg) reduces TFK-1 tumor growth significantly relative to vehicle control. Merestinib (LY2801653) inhibits the growth of intra- and extrahepatic CCC xenograft tumors[2]. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|